Kazia Therapeutics to release PNOC022 clinical study abstract

Kazia Therapeutics announced that the Society of Neuro-Oncology 2023 Annual Meeting late breaking abstract entitled “PNOC022: a combination therapy trial using an adaptive platform design for patients with diffuse midline gliomas, or DMGs, at initial diagnosis, post-radiation therapy and at time of therapy” was released by the conference organizers on 10 November 2023. The preliminary results from a single cohort in this Pacific Pediatric Neuro-Oncology Consortium, or PNOC, sponsored cooperative group clinical study will be presented on Sunday, 19 November 2023 in Vancouver, Canada. Sixty-eight children and young adults with DMG who completed standard of care radiation treatment received paxalisib and ONC201. The abstract reported that median overall survival from time of diagnosis was 16.5 months. Key Points from the Abstract include: 68 patients with biopsy-proven DMG were enrolled between November 2021 and June 2023; Median OS from time of diagnosis was 16.5 months with a median follow-up time of 9.9 months; most common grade 3 and above treatment-related adverse events were decreased neutrophil count; mucositis; and, colitis, drug reaction with eosinophilia and systemic symptoms, decreased lymphocyte count, hyperglycemia, and hypokalemia.